Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.32 |
| ▸ | FYN | P06241 | 2/20 | 0.32 |
| ▸ | VCP | P55072 | 2/20 | 0.32 |
| ▸ | YES1 | P07947 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288971 | 0.83 | MAPT (0.41) | LMNAMAPTMAPK14ALDH1A1KDM4E | |
| SCHEMBL6361331 | 0.83 | FABP4 (0.43) | MAPTALDH1A1TSHR | |
| SCHEMBL6289234 | 0.81 | RIPK2 (0.44) | HPGDSMN1; SMN2MAPTALDH1A1KDM4E | |
| SCHEMBL6289740 | 0.81 | POLB (0.49) | LMNAHPGDSMN1; SMN2MAPTKDM4E | |
| SCHEMBL6292692 | 0.81 | MAPT (0.39) | LMNAHPGDSMN1; SMN2MAPTMAPK14 | |
| SCHEMBL6292828 | 0.80 | EDNRB (0.32) | LMNAHPGDSMN1; SMN2HTT | |
| SCHEMBL6289615 | 0.80 | MAPT (0.48) | HPGDSMN1; SMN2MAPTRAB9A | |
| SCHEMBL6288927 | 0.78 | MAPK14 (0.45) | LMNAHPGDSMN1; SMN2MAPTMAPK14 | |
| SCHEMBL6288919 | 0.74 | METAP2 (0.37) | LMNAHPGDSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL6293046 | 0.73 | EDNRA (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962923-B2 | Pyrazole compositions | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030232848-A1 | Pyrazole compositions | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| US-6573270-B1 | Endothelin receptor antagonists | PFIZER INC. | 2003-06-03 | — | — | US | disclosed |
| EP-1072597-A1 | Pyrazoles and their use as endothelin antagonists | Pfizer Limited (GB) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232848-A1 | Pyrazole compositions | EDNRB, EDNRA, AGTR1 | LMNA 2329/4885HPGD 1065/4885SMN1; SMN2 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.